We are monitoring the impact of COVID-19 on MEA Biomarkers Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 169
Share on
Share on

Middle East & Africa Biomarkers Market Research Report – Segmented By Product, Type, Disease Indications & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 169
Pages: 145

MEA Biomarkers Market Size (2021 to 2026)

The size of the biomarkers market in the Middle East & Africa region is expected to reach USD 7.98 billion by 2026 from USD 3.92 billion in 2021, growing at a CAGR of 15.29% during the forecast period.

The high prevalence of cancer and heart problems in the MEA region has increased the demand for biomarkers. The technological advancements in medical fields are the major factors attributed to the MEA biomarkers market growth. The increase in cancer cases worldwide has increased the need for technology for early diagnosis and successful treatment. According to the World Cancer Research Fund International, there have been 18 million cases worldwide in 2018. Therefore, the use of biomarkers in oncology has been more prevalent than any other disease. In addition, the rising awareness for prevention and cure for cancer is of the utmost importance to governments and pharmaceutical companies in the region. There are many types of cancer, and among them, breast cancer, lung cancer, and prostate cancer are the most common. The most common cancers are breast, bladder, and liver cancers in North Africa; prostate. Lung and colorectal cancers are more prevalent in southern Africa, while cancer of the esophagus and cervix is most common in Eastern Africa. In South Africa, death rates from prostate and cervical cancer have increased over time.

Several factors such as sedentary lifestyle changes, poor eating habits, increase in smoking, and genetic predilection has given rise to more cardiovascular diseases in the past several decades. According to the WHO, cardiovascular disease (CVD) kills 18.2 million each year, equivalent to 32% of all deaths worldwide. There is high demand for cardiac biomarkers in the region due to improved healthcare facilities. For example, in 2020, there were 1,855,600 new cases worldwide. The death rate from cardiovascular disease was also high in Saudi Arabia, the United Arab Emirates, Bahrain, and Qatar 43%, 39%, 33%, and 24%, respectively, the government and pharmaceutical companies are spending heavily to provide high-quality treatment, which ultimately leads to the growth of the biomarker market in MEA region. Biomarkers have been used beyond the research laboratory to monitor disease status, prompt diagnosis, and efficient treatment. Hence, long-term cancer treatment procedures are likely to boost the growth of the MEA biomarkers market.

However, the higher level of investment required for research and development of biomarkers for various fields and the lack of developed facilities may reduce the market's growth rate during the forecast period. In addition, collecting the data for clinical validity is a time-consuming process, which is further complicated by the lack of regulated authorities. All of these factors can present a significant restraint for the MEA biomarkers market.

This research report on the MEA biomarkers market has been segmented and sub-segmented into the following categories:

By Product: 

  • Consumables
  • Software
  • Services

By Type: 

  • Safety Biomarkers
  • Efficacy Biomarkers
  • Validation Biomarkers

By Application: 

  • Diagnostics Developments
  • Drug Discovery & Developments
  • Personalized Medicine
  • Disease Risk Assessment

By Disease Indications: 

  • Cancer
  • Cardiovascular
  • Neurological
  • Immunological Disorders

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

The biomarkers market in UAE is expected to grow at a lucrative CAGR during the forecast period, attributed to the increasing number of international research organizations in the region, sufficient funds for clinical trials, and reasonable healthcare expenditures. As a result, the UAE market is expected to remain the dominant market share in the MEA region. Current health expenditure estimates include the health goods and services consumed each year. The UAE's healthcare expenditure for 2019 was $ 1,858, an increase of 10.22% from 2018. This will increase the number of biomarker production and distribution, creating enormous opportunities for regional market growth.

In 2020, Saudi Arabia accounted for a good share of the market. Saudi Arabia's GDP for 2019 had an 8.4% increase leading to $ 48 billion than the $ 43.2 billion in 2018.  Much of this region can be attributed to the increasing use of biomarkers in personalized medicine, the high rate of disposable income, and a higher rate of adoption of biomarkers for cancer diagnosis.

KEY MARKET PLAYERS:

A few of the prominent companies operating in the MEA Biomarkers Market profiled in this report are Bio-Rad Laboratories (U.S.), Qiagen N.V. (Netherlands), Enzo Biochem (U.S.), PerkinElmer, Inc. (U.S.), Merck & Co, Inc. (U.S.), EKF Diagnostics Holdings plc. (U.S.), Meso Scale Diagnostics, LLC (U.S.), Singulex, Inc. (U.S.), BioSims Technologies (France), Cisbio Bioassays (France), and Signosis, Inc. (U.S.).

  1. Introduction

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                          

                1.4 General Study Assumptions                                                

  1. Research Methodology

                2.1 Introduction                                                               

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                           

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                      

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

  1. Overview

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 New Developments                                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                                              

  1. Market Segmentation

                5.1          Product                                               

                                5.1.1 Introduction                                           

                                5.1.2 Consumables                                         

                                5.1.3 Software                                  

                                5.1.4 Services     Growth Hormone Therapy                         

                5.2          Type                                     

                                5.2.1 Introduction                                           

                                5.2.2 Safety Biomarkers                                               

                                5.2.3 Efficacy Biomarkers                                             

                                5.2.4 Validation Biomarkers                                        

                5.3          Application                                        

                                5.3.1 Introduction                                           

                                5.3.2 Diagnostics Development                                 

                                5.3.3 Drug Discovery and Development                                

                                5.3.4 Personalised Medicine                                      

                                5.3.5 Disease Risk Assessment                                  

                                5.3.6 Other Applications                                               

                5.4          Disease Indications                                        

                                5.4.1 Introduction                                           

                                5.4.2 Cancer                                      

                                5.4.3 CardiovascularDisorders                                    

                                5.4.4 Neurological Disorders                                       

                                5.4.5 Immunological Disorders                                  

                                5.4.6 Other Diseases                                      

  1. Geographical Analysis

                6.1 Introduction                                                               

                6.2 Middle-East                                                                

                6.3 South Africa                                                               

                6.4 Rest of Middle East & Africa                                                

  1. Strategic Analysis

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                       

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                                              

                                7.2.5 Competitive Rivalry within the Industry                                     

  1. Market Leaders' Analysis

                8.1 Bio-Rad Laboratories (U.S.)                                 

                                8.1.1 Overview                                 

                                8.1.2 Product Analysis                                   

                                8.1.3 Strategic Evaluation and Operations                                            

                                8.1.4 Financial analysis                                  

                                8.1.5 Legal issues                                             

                                8.1.6 Recent Developments                                       

                                8.1.7 SWOT analysis                                       

                                8.1.8 Analyst View                                          

                8.2 Qiagen N.V. (Netherlands)                                  

                8.3 Enzo Biochem (U.S.)                                               

                8.4 PerkinElmer, Inc. (U.S.)                                         

                8.5 Merck & Co, Inc. (U.S.)                                          

                8.6 EKF Diagnostics Holdings plc. (U.S.)                                  

                8.7 Meso Scale Diagnostics, LLC (U.S.)                                    

                8.8 Singulex, Inc. (U.S.)                                 

                8.9 BioSims Technologies (France)                                           

                8.10 Cisbio Bioassays (France)                                   

                8.11 Signosis, Inc. (U.S.)                                               

  1. Competitive Landscape

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                         

                9.4 New Product Launches                                                         

  1. Expert Opinions

                10.1 Market Outlook                                                     

                10.2 Investment Opportunities                                                 

     Appendix                                                                           

  1. List of Tables
  2. List of Figures
  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Biomarkers Market By Region, From 2021 to 2026 (USD Million)
  2. Middle East & Africa Biomarkers Market By Product, From 2021 to 2026 (USD Million)
  3. Middle East & Africa Consumables Market By Region, From 2021 to 2026 (USD Million)
  4. Middle East & Africa Software Market By Region, From 2021 to 2026 (USD Million)
  5. Middle East & Africa Services Market By Region, From 2021 to 2026 (USD Million)
  6. Middle East & Africa Biomarkers Market By Type, From 2021 to 2026 (USD Million)
  7. Middle East & Africa Safety Biomarkers Market By Region, From 2021 to 2026 (USD Million)
  8. Middle East & Africa Efficacy Biomarkers Market By Region, From 2021 to 2026 (USD Million)
  9. Middle East & Africa Validation Biomarkers Market By Region, From 2021 to 2026 (USD Million)
  10. Middle East & Africa Biomarkers Market By Application, From 2021 to 2026 (USD Million)
  11. Middle East & Africa Diagnostics Development Market By Region, From 2021 to 2026 (USD Million)
  12. Middle East & Africa Drug Discovery and Development Market By Region, From 2021 to 2026 (USD Million)
  13. Middle East & Africa Personalised Medicine Market By Region, From 2021 to 2026 (USD Million)
  14. Middle East & Africa Disease Risk Assessment Market By Region, From 2021 to 2026 (USD Million)
  15. Middle East & Africa Other Applications Market By Region, From 2021 to 2026 (USD Million)
  16. Middle East & Africa Biomarkers Market By Disease Indications, From 2021 to 2026 (USD Million)
  17. Middle East & Africa Cancer Market By Region, From 2021 to 2026 (USD Million)
  18. Middle East & Africa Cardiovascular Disorders Market By Region, From 2021 to 2026 (USD Million)
  19. Middle East & Africa Neurological Disorders Market By Region, From 2021 to 2026 (USD Million)
  20. Middle East & Africa Immunological Disorders Market By Region, From 2021 to 2026 (USD Million)
  21. Middle East & Africa Other Diseases Market By Region, From 2021 to 2026 (USD Million)
  22. Middle East Biomarkers Market By Product, From 2021 to 2026 (USD Million)
  23. Middle East Biomarkers Market By Type, From 2021 to 2026 (USD Million)
  24. Middle East Biomarkers Market By Application, From 2021 to 2026 (USD Million)
  25. Middle East Biomarkers Market By Disease Indications, From 2021 to 2026 (USD Million)
  26. South Africa Biomarkers Market By Product, From 2021 to 2026 (USD Million)
  27. South Africa Biomarkers Market By Type, From 2021 to 2026 (USD Million)
  28. South Africa Biomarkers Market By Application, From 2021 to 2026 (USD Million)
  29. South Africa Biomarkers Market By Disease Indications, From 2021 to 2026 (USD Million)
  30. Rest of Middle East & Africa Biomarkers Market By Product, From 2021 to 2026 (USD Million)
  31. Rest of Middle East & Africa Biomarkers Market By Type, From 2021 to 2026 (USD Million)
  32. Rest of Middle East & Africa Biomarkers Market By Application, From 2021 to 2026 (USD Million)
    1. Rest of Middle East & Africa Biomarkers Market By Disease Indications, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample